Target intelligence / Profile preview

Malic enzyme 3, NADP(+)-dependent, mitochondrial (ME3)

Target
ME3
Molecular classification
Enzyme, Mitochondrial enzyme, Oxidoreductase
01

Overview

Malic enzyme 3 (ME3) is a mitochondrial NADP(+)-dependent enzyme that catalyzes the oxidative decarboxylation of malate to pyruvate, generating NADPH in the process. ME3 plays key roles in energy metabolism, redox homeostasis, and supporting biosynthetic reactions by supplying reducing equivalents. Structurally, ME3 assembles into a tetramer and differs from its isoforms by being non-allosteric and having unique domain arrangements—a feature considered important for future drug development. Although not yet a target of approved drugs, ME3 has attracted attention as a therapeutic target in pancreatic cancer due to its role in cellular metabolic reprogramming; its structural characterization provides a basis for the rational design of selective inhibitors

Other names
Malic enzyme 3NADP-dependent malic enzyme, mitochondrialME3NADP-MEMalate dehydrogenase (oxaloacetate-decarboxylating) (NADP(+))Pyruvic-malic carboxylasemitochondrial NADP(+)-dependent malic enzyme 3
02

Mechanism of action

Hypothetical future mechanism: Small molecule inhibitors may bind non-allosteric sites, interfere with NADP(+) binding, or stabilize inactive conformations

03

Biological functions

Cellular energy regulationRedox homeostasisBiosynthetic processesProduction of NADPHOxidative decarboxylation of malate to pyruvateMaintenance of cellular metabolic balance, including neutralization of reactive oxygen species
04

Disease associations

CancerPotential roles in other diseases where mitochondrial metabolism and redox regulation are involved
05

Safety considerations

No specific safety concerns reported for drug targeting ME3, but general concerns when targeting mitochondrial enzymes include potential disruption of metabolic homeostasis and redox regulation
06

Interacting drugs

None currently approved or widely reported
07

Biomarkers

None currently validated or described

Beyond the preview

Go deeper on Malic enzyme 3, NADP(+)-dependent, mitochondrial (ME3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Malic enzyme 3, NADP(+)-dependent, mitochondrial (ME3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call